{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:58:08Z","timestamp":1763535488988},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.semcancer.2017.12.009","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T13:10:56Z","timestamp":1513429856000},"page":"241-252","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"P2","title":["Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers"],"prefix":"10.1016","volume":"52","author":[{"given":"Belinda","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Li","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Tie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Putoczki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Christie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2015","key":"10.1016\/j.semcancer.2017.12.009_bib0005","first-page":"87","article-title":"Global cancer statistics","volume":"65","author":"Torre","year":"2012","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0010","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0020","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","article-title":"Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4)","volume":"110","author":"O'Day","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0025","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.21155","article-title":"CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction","volume":"117","author":"Contardi","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0030","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.immuni.2016.05.002","article-title":"Coinhibitory pathways in the B7-CD28 ligand-receptor family","volume":"44","author":"Schildberg","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0035","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0040","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0045","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0050","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"July (6349)","key":"10.1016\/j.semcancer.2017.12.009_bib0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0060","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0065","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","article-title":"Gastric cancer, version 3.2016 NCCN clinical practice guidelines in oncology","volume":"14","author":"Ajani","year":"2016","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0070","series-title":"WHO Classification of Tumours of the Digestive System","author":"Bosman","year":"2010"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0075","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/1055-9965.EPI-10-0012","article-title":"Esophageal adenocarcinoma incidence: are we reaching the peak?","volume":"19","author":"Pohl","year":"2010","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10552-009-9458-0","article-title":"Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan","volume":"21","author":"Lu","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0085","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0090","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Bass","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma","volume":"541","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0100","first-page":"399","article-title":"Tetherin\/BST-2 promotes dendritic cell activation and function during acute retrovirus infection","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0110","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/gut.51.3.316","article-title":"Inflammatory gradient in Barrett's oesophagus: implications for disease complications","volume":"51","author":"Fitzgerald","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0120","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0125","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.MP.0000076980.73826.C0","article-title":"Lymphocyte-rich gastric cancer: associations with Epstein-Barr Virus, microsatellite instability, histology, and survival","volume":"16","author":"Grogg","year":"2003","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0130","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.cgh.2015.04.015","article-title":"Features of gastric carcinoma with lymphoid stroma associated with Epstein-Barr Virus","volume":"13","author":"Lim","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0145","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0150","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/annonc\/mdv610","article-title":"Prognostic value of tumor-infiltrating lymphocytes in Epstein\u2013Barr virus-associated gastric cancer","volume":"27","author":"Kang","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0155","first-page":"10","article-title":"Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma","volume":"7","author":"Jiang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0160","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10120-016-0594-4","article-title":"Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy","volume":"20","author":"Giampieri","year":"2016","journal-title":"Gastric Cancer"},{"issue":"2015","key":"10.1016\/j.semcancer.2017.12.009_bib0165","first-page":"259","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group","volume":"26","author":"Salgado","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0170","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.critrevonc.2016.11.016","article-title":"Tumor infiltrating lymphocytes in gastrointestinal tumors: controversies and future clinical implications","volume":"110","author":"Solinas","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"November (10)","key":"10.1016\/j.semcancer.2017.12.009_bib0180","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1038\/sj.bjc.6604738","article-title":"Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer","volume":"99","author":"Lee","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0185","first-page":"11","article-title":"Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients","volume":"5","author":"Hennequin","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0190","doi-asserted-by":"crossref","first-page":"e1631","DOI":"10.1097\/MD.0000000000001631","article-title":"Tumor-infiltrating immune cells are associated with prognosis of gastric cancer","volume":"94","author":"Liu","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0195","doi-asserted-by":"crossref","first-page":"e1100789","DOI":"10.1080\/2162402X.2015.1100789","article-title":"Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma","volume":"5","author":"Schler","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0200","article-title":"Patterns of PD-L1 expression and CD8T cell infiltration in gastric adenocarcinomas and associated immune stroma","author":"Thompson","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0205","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0210","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/1471-230X-9-65","article-title":"Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia","volume":"9","author":"Haas","year":"2009","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0215","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.humpath.2013.09.004","article-title":"Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers","volume":"45","author":"Kim","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0220","doi-asserted-by":"crossref","first-page":"e74430","DOI":"10.1371\/journal.pone.0074430","article-title":"CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0225","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.29481","article-title":"Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients","volume":"137","author":"Jia","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0230","first-page":"87","article-title":"Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0235","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0245","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00262-013-1491-x","article-title":"Critical role of spatial interaction between CD8+ and Foxp3+ cells in human gastric cancer: the distance matters","volume":"63","author":"Feichtenbeiner","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0250","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1556-0864(15)31573-2","article-title":"Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer","volume":"1","author":"Tsao","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0255","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2014-308252","article-title":"Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas","volume":"64","author":"Lin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0260","doi-asserted-by":"crossref","first-page":"32925","DOI":"10.18632\/oncotarget.9076","article-title":"Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers","volume":"7","author":"Derks","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0265","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0270","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0275","doi-asserted-by":"crossref","first-page":"292","DOI":"10.14694\/EDBK_175231","article-title":"Immunotherapy for esophageal and gastric cancer","volume":"37","author":"Kelly","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"2015","key":"10.1016\/j.semcancer.2017.12.009_bib0280","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0285","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0290","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0295","first-page":"280","article-title":"Current and future systemic treatment options in metastatic pancreatic cancer","volume":"5","author":"Arslan","year":"2014","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0300","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1200\/JCO.2009.21.9022","article-title":"Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment","volume":"27","author":"Philip","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0305","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0310","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0315","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0320","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0325","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0330","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0335","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/CAD.0000000000000178","article-title":"Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation","volume":"26","author":"Vyas","year":"2015","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0340","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1634\/theoncologist.2011-0185","article-title":"An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions","volume":"16","author":"Lowery","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0345","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0350","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0355","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0360","first-page":"1501","article-title":"Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER","volume":"152","author":"Goggins","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0365","doi-asserted-by":"crossref","first-page":"e46002","DOI":"10.1371\/journal.pone.0046002","article-title":"Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma","volume":"7","author":"Laghi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0370","first-page":"3139","article-title":"Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability","volume":"61","author":"Yamamoto","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0375","first-page":"2536","article-title":"Prognostic value of microsatellite instability in resectable pancreatic cancer","volume":"8","author":"Nakata","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0380","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0385","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0390","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1101\/gr.165985.113","article-title":"Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival","volume":"24","author":"Brown","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0395","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0400","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/srep35848","article-title":"Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma","volume":"6","author":"Bailey","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0405","first-page":"110","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"7","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0410","first-page":"2969","article-title":"Progression model for pancreatic cancer","volume":"6","author":"Hruban","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0415","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ccr.2004.09.028","article-title":"Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis","volume":"6","author":"Sparmann","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0420","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0425","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0430","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0435","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0440","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000236012","article-title":"Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1\/CXCR4 axis","volume":"10","author":"Gao","year":"2010","journal-title":"Pancreatology"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0445","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ijc.24040","article-title":"CXCL8\/IL-8 and CXCL12\/SDF-1? Co-operatively promote invasiveness and angiogenesis in pancreatic cancer","volume":"124","author":"Matsuo","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0450","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/ncb3340","article-title":"Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis","volume":"18","author":"Nielsen","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0455","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15252\/emmm.201505948","article-title":"Pancreatic cancer microenvironment, to target or not to target?","volume":"8","author":"Carr","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0460","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1158\/0008-5472.CAN-07-0175","article-title":"Dynamics of the immune reaction to pancreatic cancer from inception to invasion","volume":"67","author":"Clark","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0465","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.1073\/pnas.1017360108","article-title":"ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors","volume":"108","author":"Bollyky","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0470","series-title":"Randomized Phase II Study of PEGPH20 Plus Nab-paclitaxel\/gemcitabine (PAG) Vs AG in Patients (Pts) with Untreated, Metastatic Pancreatic Ductal Adenocarcinoma (mPDA)","first-page":"1","author":"Hingorani","year":"2017"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0475","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11912-017-0608-3","article-title":"Targeting the tumor stroma: the biology and clinical development of pegylated recombinant human hyaluronidase (PEGPH20)","volume":"19","author":"Wong","year":"2017","journal-title":"Curr. Oncol. Rep."},{"issue":"May (11)","key":"10.1016\/j.semcancer.2017.12.009_bib0480","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/bjc.2015.145","article-title":"Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer","volume":"112","author":"Hiaoka","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0485","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MPA.0000000000000423","article-title":"Impact of intratumoral inflammation on survival after pancreatic cancer resection","volume":"45","author":"Hart","year":"2016","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0490","doi-asserted-by":"crossref","first-page":"e91551","DOI":"10.1371\/journal.pone.0091551","article-title":"An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma","volume":"9","author":"Tang","year":"2014","journal-title":"PLoS One"},{"issue":"March (4)","key":"10.1016\/j.semcancer.2017.12.009_bib0495","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0500","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/00006676-200401000-00023","article-title":"CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma","volume":"28","author":"Fukunaga","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0505","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/1471-2407-13-436","article-title":"The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays","volume":"13","author":"Tewari","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0510","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00262-011-1028-0","article-title":"Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13","volume":"60","author":"Gabitass","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0515","doi-asserted-by":"crossref","first-page":"e96565","DOI":"10.1371\/journal.pone.0096565","article-title":"Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment","volume":"9","author":"Shibuya","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0520","doi-asserted-by":"crossref","first-page":"e0131403","DOI":"10.1371\/journal.pone.0131403","article-title":"PD-L1 and survival in solid tumors: a meta-analysis","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0525","doi-asserted-by":"crossref","first-page":"71198","DOI":"10.18632\/oncotarget.11685","article-title":"Prognostic value of PDL1 expression in pancreatic cancer","volume":"7","author":"Birnbaum","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0530","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0535","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2008.03.056","article-title":"Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer","volume":"268","author":"Loos","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0540","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0545","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0550","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0555","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Opinion: immunotherapy and chemotherapy? A practical partnership","volume":"5","author":"Lake","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0560","article-title":"Ipilimumab and gemcitabine for advanced pancreas cancer: a phase Ib study","volume":"33","author":"Kalyan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0565","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0570","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0575","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-Infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0580","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-13-0525","article-title":"Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis","volume":"19","author":"Sanford","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0585","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4_suppl","key":"10.1016\/j.semcancer.2017.12.009_bib0590","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.35.4_suppl.276","article-title":"Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer","volume":"35","author":"Noel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0595","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1479-5876-7-93","article-title":"Activation of human B cells by the agonist CD40 antibody CP-870, 893 and augmentation with simultaneous toll-like receptor 9 stimulation","volume":"7","author":"Carpenter","year":"2009","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0600","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0605","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3389\/fonc.2015.00034","article-title":"OX40 agonists and combination immunotherapy putting the pedal to the metal","volume":"5","author":"Linch","year":"2015","journal-title":"Front. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2017.12.009_bib0610","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3100","article-title":"A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors","volume":"35","author":"Curti","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0615","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","article-title":"Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors","volume":"34","author":"Naing","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0620","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","article-title":"Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity","volume":"115","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0625","doi-asserted-by":"crossref","first-page":"9941","DOI":"10.1007\/s11033-012-1862-y","article-title":"T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer","volume":"39","author":"Tong","year":"2012","journal-title":"Mol. Biol. Rep."},{"issue":"15_suppl","key":"10.1016\/j.semcancer.2017.12.009_bib0630","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e14611","article-title":"Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers","volume":"35","author":"Datar","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0635","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen\u2013specific CD8 +T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0640","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"issue":"Suppl. 15","key":"10.1016\/j.semcancer.2017.12.009_bib0645","article-title":"Systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic cancer","volume":"34","author":"Nesselhut","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0650","first-page":"1","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma","volume":"2014","author":"Kikuchi","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0655","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"24","author":"Kamangar","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0660","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0665","first-page":"1","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0670","series-title":"Phase I\/II Study of Durvalumab and Tremelimumab in Patients with Unresectable Hepatocellular Carcinoma (HCC): Phase I Safety and Efficacy Analyses","author":"Kelley","year":"2017"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0675","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0680","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0685","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/hep.26731","article-title":"Immunodominance and functional alterations of tumor-associated antigen-specific CD8 +T-cell responses in hepatocellular carcinoma","volume":"59","author":"Flecken","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0690","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0695","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","article-title":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma","volume":"169","author":"Ally","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0700","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic landscape and biomarkers of hepatocellular carcinoma","volume":"149","author":"Zucman-Rossi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0705","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0710","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/MEG.0b013e328324b6a2","article-title":"Spontaneous regression of hepatocellular carcinoma: a systematic review","volume":"21","author":"Oquiena","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0715","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1477-2574.2012.00478.x","article-title":"Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response","volume":"14","author":"Huz","year":"2012","journal-title":"Hpb"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0720","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.510270214","article-title":"Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration","volume":"27","author":"Wada","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0725","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1158\/2326-6066.CIR-15-0110","article-title":"Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC","volume":"4","author":"Gabrielson","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0730","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","article-title":"Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection","volume":"25","author":"Gao","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0735","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1136\/gutjnl-2015-310814","article-title":"Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma","volume":"66","author":"Garnelo","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0740","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Gao","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0745","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4143\/crt.2016.066","article-title":"Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma","volume":"49","author":"Jung","year":"2017","journal-title":"Cancer Res Treat."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0750","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/hep.28710","article-title":"Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features","volume":"64","author":"Calderaro","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0755","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0760","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/carcin\/bgh035","article-title":"Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers","volume":"25","author":"Chiappini","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0765","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.3748\/wjg.v11.i20.3034","article-title":"Clinicopathological significance of loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in China","volume":"11","author":"Zhang","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0770","first-page":"543","article-title":"Infrequent widespread microsatellite instability in hepatocellular carcinomas","volume":"16","author":"Yamamoto","year":"2000","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0775","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/cgt.2016.63","article-title":"Gene-expression profiling to predict responsiveness to immunotherapy","volume":"24","author":"Jamieson","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0780","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11912-016-0509-x","article-title":"Emerging tissue and blood-based biomarkers that may predict response to immune checkpoint inhibition","volume":"18","author":"Friedman","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0785","doi-asserted-by":"crossref","first-page":"45283","DOI":"10.18632\/oncotarget.9942","article-title":"Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: a systematic review and meta-analysis of observational studies","volume":"7","author":"Qi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0795","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjd.14155","article-title":"High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma","volume":"174","author":"Zaragoza","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0800","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1186\/s12894-016-0192-0","article-title":"Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma","volume":"17","author":"Kuzman","year":"2017","journal-title":"BMC Urol."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0805","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.dld.2016.07.010","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis","volume":"48","author":"Wang","year":"2016","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0810","doi-asserted-by":"crossref","first-page":"e0168798","DOI":"10.1371\/journal.pone.0168798","article-title":"Is adjuvant cellular immunotherapy essential after TACE-predominant minimally-invasive treatment for hepatocellular carcinoma? A systematic meta-analysis of studies including 1774 patients","volume":"11","author":"Ding","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0815","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0820","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2017.12.009_bib0825","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1158\/1078-0432.CCR-16-3079","article-title":"Challenges and opportunities in adapting clinical trial design for immunotherapies","volume":"23","author":"Siu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2017.12.009_bib0830","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.ejso.2017.06.012","article-title":"Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre","volume":"43","author":"Itchins","year":"2017","journal-title":"Eur. J. Surg. Oncol. (EJSO)"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X17301232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X17301232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T07:38:47Z","timestamp":1536737927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X17301232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":166,"alternative-id":["S1044579X17301232"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2017.12.009","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2017.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}